Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
Schildcrout J, Denny J, Bowton E, Gregg W, Pulley J, Basford M, Cowan J, Xu H, Ramirez A, Crawford D, Ritchie M, Peterson J, Masys D, Wilke R, Roden D. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clinical Pharmacology & Therapeutics 2012, 92: 235-242. PMID: 22739144, PMCID: PMC3785311, DOI: 10.1038/clpt.2012.66.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterAdverse eventsPreemptive genotypingPotential adverse eventsUniversity Medical CenterHome patientsPharmacogenetic associationsMedical CenterVariant allelesMedicationsDrug outcomesPatient safetyDrug decision makingRelevant genetic variantsRoutine integrationTarget drugsGenetic variantsOutcomesFrequency of opportunitiesGenotypingSafetyPrescribingPatientsCohortPharmacogenetics